Literature DB >> 16885191

Intravitreal triamcinolone and laser photocoagulation for retinal angiomatous proliferation.

T R Krieglstein1, A Kampik, M Ulbig.   

Abstract

BACKGROUND: Recently, the entity of retinal angiomatous proliferation (RAP) as a subtype of exudative age-related macular degeneration was described, but no treatment options have been established as yet. The only two therapeutic modalities being discussed are surgical lysis of the feeding arteriole and draining venule, and the use of photodynamic therapy combined with intravitreal triamcinolone injection. AIM: To examine focal laser treatment of early extrafoveal intraretinal neovascularisation of RAP.
METHODS: Prospective case series. We included 13 consecutive patients with an extrafoveal RAP stage I lesion. All patients underwent a complete ophthalmic examination, including fluorescein angiography and optical coherence tomography (OCT) III before treatment and at 2 weeks, 1, 2 and 4 months afterwards. In cases with marked macular oedema (>350 mum retinal thickening in OCT III, r = 12), intravitreal injection of 4 mg triamcinolone was given before focal laser treatment to reduce the oedema.
RESULTS: This case series indicates anatomical improvement or stabilisation in patients with an extrafoveal RAP lesion after treatment. Initial visual acuity ranged from 0.1 to 0.6 on the Snellen chart. By calculating logarithmic values, visual acuity was seen to be improved in five cases (2 to 5 log lines), deteriorated in four cases (-2 to 5 log lines) and stabilised in four cases (-1 to +1 log line change). Exudation on fluorescein angiography was stopped in 11 cases.
CONCLUSIONS: This preliminary case series suggests laser photocoagulation combined with prior intravitreal triamcinolone injection as a viable treatment option for RAP stage I. In cases with marked macular oedema, intravitreal triamcinolone injection improved visual acuity. For long-term stabilisation, additional laser treatment is mandatory. These preliminary results warrant a more detailed prospective clinical trial.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16885191      PMCID: PMC1857478          DOI: 10.1136/bjo.2006.092536

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  12 in total

1.  Acute retinal pigment epithelial tear after photodynamic therapy.

Authors:  A Pece; U Introini; F Bottoni; R Brancato
Journal:  Retina       Date:  2001       Impact factor: 4.256

2.  Retinal angiomatous proliferation in age-related macular degeneration.

Authors:  L A Yannuzzi; S Negrão; T Iida; C Carvalho; H Rodriguez-Coleman; J Slakter; K B Freund; J Sorenson; D Orlock; N Borodoker
Journal:  Retina       Date:  2001       Impact factor: 4.256

3.  Imaging of chorioretinal anastomoses in vascularized retinal pigment epithelium detachments.

Authors:  D Kuhn; I Meunier; G Soubrane; G Coscas
Journal:  Arch Ophthalmol       Date:  1995-11

4.  Recurrent retinal angiomatous proliferation after surgical ablation.

Authors:  Susumu Sakimoto; Fumi Gomi; Hirokazu Sakaguchi; Yasuo Tano
Journal:  Am J Ophthalmol       Date:  2005-05       Impact factor: 5.258

5.  Retinal angiomatous proliferation with a cilioretinal artery anastomosis: an unusual presentation.

Authors:  Nicola G Ghazi; Brian P Conway
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-12-17       Impact factor: 3.117

6.  Remodeling of the vascular channels in retinal angiomatous proliferations treated with intravitreal triamcinolone acetonide and photodynamic therapy.

Authors:  Ferdinando Bottoni; Mary Romano; Amedeo Massacesi; Fulvio Bergamini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-04-12       Impact factor: 3.117

7.  Deep retinal vascular anomalous complexes in advanced age-related macular degeneration.

Authors:  M E Hartnett; J J Weiter; G Staurenghi; A E Elsner
Journal:  Ophthalmology       Date:  1996-12       Impact factor: 12.079

8.  Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration.

Authors:  J S Slakter; L A Yannuzzi; U Schneider; J A Sorenson; A Ciardella; D R Guyer; R F Spaide; K B Freund; D A Orlock
Journal:  Ophthalmology       Date:  2000-04       Impact factor: 12.079

9.  Retinal angiomatous proliferation: clinical characteristics and treatment options.

Authors:  Megan A Hunter; Mark T Dunbar; Phillip J Rosenfeld
Journal:  Optometry       Date:  2004-09

10.  Surgical ablation of retinal angiomatous proliferation.

Authors:  J Luigi Borrillo; Arunan Sivalingam; Adam Martidis; Jay L Federman
Journal:  Arch Ophthalmol       Date:  2003-04
View more
  5 in total

1.  Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).

Authors:  Lazaros Konstantinidis; Evangelia Mameletzi; Irmela Mantel; Jean-Antoine Pournaras; Leonidas Zografos; Aude Ambresin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-04-29       Impact factor: 3.117

2.  [Anti-VEGF treatment for retinal angiomatous proliferation].

Authors:  A Wolf; D Kook; T Kreutzer; A Gandorfer; C Haritoglou; A Kampik; M Ulbig
Journal:  Ophthalmologe       Date:  2008-09       Impact factor: 1.059

Review 3.  [Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series].

Authors:  C H Meyer; H-M Helb; N Eter
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

4.  The effect of triamcinolone acetonide on laser-induced choroidal neovascularization in mice using a hypoxia visualization bio-imaging probe.

Authors:  Shinsuke Takata; Tomomi Masuda; Shinsuke Nakamura; Takahiro Kuchimaru; Kazuhiro Tsuruma; Masamitsu Shimazawa; Hideko Nagasawa; Shinae Kizaka-Kondoh; Hideaki Hara
Journal:  Sci Rep       Date:  2015-04-30       Impact factor: 4.379

5.  Effects of triamcinolone acetonide on vessels of the posterior segment of the eye.

Authors:  Fatemeh Valamanesh; Marianne Berdugo; Florian Sennlaub; Michèle Savoldelli; Cyndie Goumeaux; Marianne Houssier; Jean-Claude Jeanny; Alicia Torriglia; Francine Behar-Cohen
Journal:  Mol Vis       Date:  2009-12-08       Impact factor: 2.367

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.